Document is current
Any future updates will be listed below
-
Authors
Cui, Jiayan
Lin, Zi Jie https://orcid.org/0009-0004-1707-6471
Ghosh, Sukanya
Du, Jianqiu https://orcid.org/0009-0001-2626-6590
Sadeesh, Roopak
Weiner, David B. https://orcid.org/0000-0002-2232-8512
Pallesen, Jesper https://orcid.org/0000-0002-3270-1587
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19 AI166916)
W. W. Smith Charitable Trust (A2404)
- License Information
-
More Information
Article History
Received: 1 July 2025
Accepted: 13 February 2026
First Online: 24 February 2026
Competing interests
: D.B.W. notes several possible competing interests, which are managed by the Wistar General Council Office COI committee. These include consulting, BOD service, speaking, which can include in-stock or monetary remuneration, and specific SRAs. Inovio Pharmaceuticals (BOD, consultant and SRA); AstraZeneca (speaker/consultant); Geneos (consultant & SRA); and possibly others that are managed by the Wistar COI Committee. D.B.W. is a member of the International Society for Vaccines, AAI, ASGCT, and AAAS, among other scientific societies. He also serves on NIH and NCI study sections and similar activities for other agencies. The remaining authors declare no competing interests.
